Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901221 | 0.91 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL13901225 | 0.91 | LMNA (0.46) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 | |
| SCHEMBL13901223 | 0.91 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL9556855 | 0.90 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6222233 | 0.90 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL13901219 | 0.90 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5566835 | 0.89 | CA12 (0.47) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 | |
| SCHEMBL13901227 | 0.88 | LMNA (0.43) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 | |
| SCHEMBL9069522 | 0.87 | CA12 (0.49) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 | |
| SCHEMBL24780787 | 0.87 | LMNA (0.47) | LMNATHRBSMN1; SMN2HIF1ASLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105498-B2 | Acylated uridine and cytidine and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2006-09-12 | — | — | US | claimed |
| US-6274563-B1 | ADMINISTERING AS ANTIDIABETIC AGENT | PRO-NEURON, INC. | 2001-08-14 | — | — | US | claimed |
| US-6258795-B1 | Acylated uridine and cytidine and uses thereof | PRO-NEURON, INC. | 2001-07-10 | — | — | US | claimed |
| JP-2894610-B2 | — | — | 1999-05-24 | — | — | JP | claimed |
| US-5470838-A | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine | PRO-NEURON, INC. (US) | 1995-11-28 | — | — | US | claimed |
| EP-0339075-B1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1993-08-18 | — | — | EP | claimed |
| EP-0339075-A4 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF. | PRO NEURON INC (US) | 1990-04-10 | — | — | EP | claimed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | claimed |
| WO-1989003837-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | claimed |
| EP-1778223-A4 | METHODS AND COMPOSITIONS FOR REDUCING TOXICITY ASSOCIATED WITH LEFLUNOMIDE TREATMENT | WILLIAMS JAMES W (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1778223-A1 | METHODS AND COMPOSITIONS FOR REDUCING TOXICITY ASSOCIATED WITH LEFLUNOMIDE TREATMENT | Williams, James W. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006014827-A1 | METHODS AND COMPOSITIONS FOR REDUCING TOXICITY ASSOCIATED WITH LEFLUNOMIDE TREATMENT | UNIV CHICAGO (US) | 2006-02-09 | — | — | WO | disclosed |
| US-6316426-B1 | NUCLEOSIDE DERIVATIVE FOR DIABETES, HEART DISEASE, CEREBROVASCULAR DISORDERS, PARKINSON'S DISEASE, INFANT RESPIRATORY DISTRESS SYNDROME AND FOR ENHANCEMENT OF PHOSPHOLIPID BIOSYNTHESIS | PRO-NEURON, INC. | 2001-11-13 | — | — | US | disclosed |
| US-6274563-B1 | ADMINISTERING AS ANTIDIABETIC AGENT | PRO-NEURON, INC. | 2001-08-14 | — | — | US | disclosed |
| US-6258795-B1 | Acylated uridine and cytidine and uses thereof | PRO-NEURON, INC. | 2001-07-10 | — | — | US | disclosed |
| US-5470838-A | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine | PRO-NEURON, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0339075-B1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | disclosed |